Novartis

BASEL, July 17, 2026 Novartis announced that the U.S. Food and Drug Administration (FDA) has granted traditional approval for...

BASEL, Switzerland, June 11, 2026 Novartis has announced positive results from the FORTITUDE Phase I/II clinical study evaluating delpacibart...

BASEL, Switzerland, June 8, 2026 Novartis announced the presentation of data from 10 scientific abstracts at the European Academy...

BASEL, Switzerland, June 1, 2026 Novartis announced that it will present new data from 31 abstracts across its expanding...

BASEL, Switzerland, May 21, 2026 Novartis announced it will present more than 65 company-sponsored and investigator-sponsored abstracts at the...

LONDON, May 12, 2026 Isomorphic Labs has secured a massive $2.1 billion Series B funding round to accelerate the...

Basel, Switzerland | April 24, 2026 In a major breakthrough for rare disease treatment, Novartis has received a positive...

BASEL, Switzerland, April 24, 2026 Novartis has achieved a major global health milestone as the World Health Organization (WHO)...

Basel, Switzerland | March 27, 2026 Strategic Acquisition Strengthens Allergy Leadership Novartis has announced a major strategic move to...

BASEL, Switzerland, March 20, 2026 Novartis announced a major strategic acquisition to strengthen its oncology portfolio, agreeing to acquire...